189 related articles for article (PubMed ID: 12386920)
1. Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells.
Devi GR; Oldenkamp JR; London CA; Iversen PL
Prostate; 2002 Nov; 53(3):200-10. PubMed ID: 12386920
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans.
Iversen PL; Arora V; Acker AJ; Mason DH; Devi GR
Clin Cancer Res; 2003 Jul; 9(7):2510-9. PubMed ID: 12855625
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.
Ko YJ; Devi GR; London CA; Kayas A; Reddy MT; Iversen PL; Bubley GJ; Balk SP
J Urol; 2004 Sep; 172(3):1140-4. PubMed ID: 15311058
[TBL] [Abstract][Full Text] [Related]
4. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
5. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity.
London CA; Sekhon HS; Arora V; Stein DA; Iversen PL; Devi GR
Cancer Gene Ther; 2003 Nov; 10(11):823-32. PubMed ID: 14605668
[TBL] [Abstract][Full Text] [Related]
6. c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model.
Sekhon HS; London CA; Sekhon M; Iversen PL; Devi GR
Lung Cancer; 2008 Jun; 60(3):347-54. PubMed ID: 18096271
[TBL] [Abstract][Full Text] [Related]
7. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
9. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW
Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962
[TBL] [Abstract][Full Text] [Related]
10. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells.
Napoli S; Negri U; Arcamone F; Capobianco ML; Carbone GM; Catapano CV
Nucleic Acids Res; 2006; 34(2):734-44. PubMed ID: 16449206
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of homeobox gene GBX2 expression inhibits human prostate cancer clonogenic ability and tumorigenicity.
Gao AC; Lou W; Isaacs JT
Cancer Res; 1998 Apr; 58(7):1391-4. PubMed ID: 9537237
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
14. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.
Shirakawa T; Gotoh A; Zhang Z; Kao C; Chung LW; Gardner TA
Urology; 2004 Mar; 63(3):613-8. PubMed ID: 15028478
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
Gao L; Zhang L; Hu J; Li F; Shao Y; Zhao D; Kalvakolanu DV; Kopecko DJ; Zhao X; Xu DQ
Clin Cancer Res; 2005 Sep; 11(17):6333-41. PubMed ID: 16144938
[TBL] [Abstract][Full Text] [Related]
16. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
Watson PA; Ellwood-Yen K; King JC; Wongvipat J; Lebeau MM; Sawyers CL
Cancer Res; 2005 Dec; 65(24):11565-71. PubMed ID: 16357166
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells.
Angelucci C; Iacopino F; Lama G; Capucci S; Zelano G; Boca M; Pistilli A; Sica G
Anticancer Res; 2004; 24(5A):2729-38. PubMed ID: 15517879
[TBL] [Abstract][Full Text] [Related]
18. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
19. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
20. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist.
Fishman P; Bar-Yehuda S; Ardon E; Rath-Wolfson L; Barrer F; Ochaion A; Madi L
Anticancer Res; 2003; 23(3A):2077-83. PubMed ID: 12894581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
